Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

New Therapeutic Options for Migraine

Author(s): Claudio Tana*, Francesco Cipollone and Maria Adele Giamberardino

Volume 29, Issue 25, 2023

Published on: 24 August, 2023

Page: [1964 - 1966] Pages: 3

DOI: 10.2174/1381612829666230821092238

Price: $65

conference banner
« Previous Next »
[1]
Steiner TJ, Stovner LJ. Global epidemiology of migraine and its implications for public health and health policy. Nat Rev Neurol 2023; 19(2): 109-17.
[http://dx.doi.org/10.1038/s41582-022-00763-1] [PMID: 36693999]
[2]
Tana C, Bentivegna E, Cho SJ, et al. Long COVID headache. J Headache Pain 2022; 23(1): 93.
[http://dx.doi.org/10.1186/s10194-022-01450-8] [PMID: 35915417]
[3]
Ailani J, Burch RC, Robbins MS. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache 2021; 61(7): 1021-39.
[http://dx.doi.org/10.1111/head.14153] [PMID: 34160823]
[4]
Diener HC, Donoghue S, Gaul C, et al. Prevention of medication overuse and medication overuse headache in patients with migraine: A randomized, controlled, parallel, allocation-blinded, multicenter, prospective trial using a mobile software application. Trials 2022; 23(1): 382.
[http://dx.doi.org/10.1186/s13063-022-06329-2]
[5]
Giamberardino M, Affaitati G, Costantini R, Cipollone F, Martelletti P. Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: Current evidence and safety profile of erenumab. J Pain Res 2017; 10: 2751-60.
[http://dx.doi.org/10.2147/JPR.S128143] [PMID: 29263689]
[6]
Chiang CC, Schwedt TJ. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants. Prog Brain Res. 2020; 255: pp. 143-70.
[http://dx.doi.org/10.1016/bs.pbr.2020.06.019] [PMID: 33008505]
[7]
Lee MJ, Al-Karagholi MAM, Reuter U. New migraine prophylactic drugs: Current evidence and practical suggestions for non-responders to prior therapy. Cephalalgia 2023; 43(2)
[http://dx.doi.org/10.1177/03331024221146315] [PMID: 36759320]
[8]
Burch RC, Ailani J, Robbins MS. Comment: The American Headache Society consensus statement: Update on integrating new migraine treatments into clinical practice. Headache 2022; 62(1): 111-2.
[http://dx.doi.org/10.1111/head.14245] [PMID: 34873692]
[9]
Begasse de Dhaem O, Takizawa T, Dodick DW. Long-term open-label and real-world studies of lasmiditan, ubrogepant, and rimegepant for the acute treatment of migraine attacks. Cephalalgia 2023; 43(2): 03331024221137092.
[http://dx.doi.org/10.1177/03331024221137092] [PMID: 36739505]
[10]
Vila-Pueyo M, Page K, Murdock PR, et al. The selective 5-HT1F receptor agonist lasmiditan inhibits trigeminal nociceptive processing: Implications for migraine and cluster headache. Br J Pharmacol 2022; 179(3): 358-70.
[http://dx.doi.org/10.1111/bph.15699] [PMID: 34600443]
[11]
Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB. Lasmiditan is an effective acute treatment for migraine. Neurology 2018; 91(24): e2222-32.
[http://dx.doi.org/10.1212/WNL.0000000000006641] [PMID: 30446595]
[12]
Goadsby PJ, Wietecha LA, Dennehy EB, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain 2019; 142(7): 1894-904.
[http://dx.doi.org/10.1093/brain/awz134] [PMID: 31132795]
[13]
Lipton RB, Munjal S, Brand-Schieber E, Tepper SJ, Dodick DW. Efficacy, tolerability, and safety of DFN-15 (celecoxib oral solution, 25 mg/ml) in the acute treatment of episodic migraine: A randomized, double-blind, placebo-controlled study. Headache 2020; 60(1): 58-70.
[http://dx.doi.org/10.1111/head.13663] [PMID: 31647577]
[14]
Yarnitsky D, Dodick DW, Grosberg BM, et al. Remote electrical neuromodulation (REN) relieves acute migraine: A randomized, double-blind, placebo-controlled, multicenter trial. Headache 2019; 59(8): 1240-52.
[http://dx.doi.org/10.1111/head.13551] [PMID: 31074005]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy